在结直肠癌（CRC）治疗中，新靶点和生物标志物亟待探索。研究人员开展了 KAT2A 在 CRC 中作用的研究，发现特定亚型 CRC 依赖 KAT2A，抑制它可阻碍肿瘤生长。这为 CRC 治疗提供新方向，有望改善患者预后。研究成果发表在《Cell Death & Differentiation》上 ...

Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both ...

Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both ...

Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A/B degrader, AUTX-703, which is being developed for the treatment of both ...